CXCR2 and neoplasm: Our findings suggest that Anwulignan mitigates BCP through a distinct synergistic mechanism, which involves the upregulation of PPARα expression to inhibit the expression of CXCR2, a reduction in tumor burden, and the promotion of osteoblast synthesis.